GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: December 5, 2003, 18:14:44 ; Search time 28.64 Seconds
(without alignments)
264.443 Million cell updates/sec

Title: US-10-084-298-2
Perfect score: 903
Sequence: 1 MAALQKSVSSFLMGTLATSC.....EIKAIGELDLLFMSLRNACI 179

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	903	100.0	179	4	US-09-870-574-2	Sequence 2, Appli
2	881	97.6	179	4	US-09-419-568F-28	Sequence 28, Appl
3	881	97.6	179	4	US-09-354-243B-28	Sequence 28, Appl
4	724	80.2	179	3	US-09-178-973B-15	Sequence 15, Appl
5	724	80.2	179	4	US-09-419-568F-27	Sequence 27, Appl
6	724	80.2	179	4	US-09-354-243B-27	Sequence 27, Appl
7	720	79.7	179	3	US-09-178-973B-16	Sequence 16, Appl
8	109	12.1	170	1	US-08-270-805C-2	Sequence 2, Appli
9	109	12.1	170	2	US-08-410-654B-2	Sequence 2, Appli
10	109	12.1	170	2	US-08-474-851-2	Sequence 2, Appli
11	109	12.1	170	2	US-08-481-560-2	Sequence 2, Appli
12	109	12.1	170	2	US-08-934-959-4	Sequence 4, Appli
13	109	12.1	170	3	US-08-170-113-2	Sequence 2, Appli
14	109	12.1	170	3	US-08-765-094C-26	Sequence 26, Appl
15	109	12.1	170	3	US-09-082-797-26	Sequence 26, Appl
16	109	12.1	170	3	US-08-643-810A-2	Sequence 2, Appli
17	109	12.1	170	4	US-09-552-613-2	Sequence 2, Appli
18	104.5	11.6	154	4	US-09-452-624A-3	Sequence 3, Appli
19	102.5	11.4	178	1	US-08-270-805C-1	Sequence 1, Appli
20	102.5	11.4	178	2	US-08-410-654B-1	Sequence 1, Appli
21	102.5	11.4	178	2	US-08-474-851-1	Sequence 1, Appli
22	102.5	11.4	178	2	US-08-481-560-1	Sequence 1, Appli
23	102.5	11.4	178	2	US-08-934-959-6	Sequence 6, Appli
24	102.5	11.4	178	3	US-08-170-113-1	Sequence 1, Appli
25	102.5	11.4	178	3	US-08-765-094C-25	Sequence 25, Appl
26	102.5	11.4	178	3	US-09-082-797-25	Sequence 25, Appl
27	102.5	11.4	178	3	US-08-643-810A-1	Sequence 1, Appli
28	102.5	11.4	178	4	US-09-552-613-1	Sequence 1, Appli
29	98.5	10.9	147	1	US-08-270-805C-4	Sequence 4, Appli
30	98.5	10.9	147	2	US-08-410-654B-4	Sequence 4, Appli
31	98.5	10.9	147	2	US-08-474-851-4	Sequence 4, Appli
32	98.5	10.9	147	2	US-08-481-560-4	Sequence 4, Appli
33	98.5	10.9	147	3	US-08-170-113-4	Sequence 4, Appli
34	98.5	10.9	147	3	US-08-643-810A-4	Sequence 4, Appli
35	98.5	10.9	147	4	US-09-552-613-4	Sequence 4, Appli
36	98.5	10.9	147	5	PCT-US93-07646-2	Sequence 2, Appli
37	98.5	10.9	166	4	US-09-452-624A-4	Sequence 4, Appli
38	97.5	10.8	160	1	US-08-270-805C-3	Sequence 3, Appli
39	97.5	10.8	160	2	US-08-410-654B-3	Sequence 3, Appli
40	97.5	10.8	160	2	US-08-474-851-3	Sequence 3, Appli
41	97.5	10.8	160	2	US-08-481-560-3	Sequence 3, Appli
42	97.5	10.8	160	3	US-08-170-113-3	Sequence 3, Appli
43	97.5	10.8	160	3	US-08-643-810A-3	Sequence 3, Appli
44	97.5	10.8	160	4	US-09-552-613-3	Sequence 3, Appli
45	97.5	10.8	160	4	US-09-452-624A-1	Sequence 1, Appli

ALIGNMENTS

RESULT 1
US-09-870-574-2
; Sequence 2, Application US/09870574
; Patent No. 6551799
; GENERAL INFORMATION:
; APPLICANT: Gurney,Austin L.
; APPLICANT: Aggarwal,Sudeepta
; APPLICANT: Xie,Ming-Hong
; APPLICANT: Maruoka,Ellen M.
; APPLICANT: Foster,Jessica S.
; APPLICANT: Goddard,Audrey
; APPLICANT: Wood,William I.
; TITLE OF INVENTION: INTERLEUKIN-22 POLYPEPTIDES, NUCLEIC ACIDS ENCODING
; TITLE OF INVENTION: THE SAME AND METHODS FOR THE TREATMENT OF PANCREATIC DISORDERS
; FILE REFERENCE: P2806-1(US)
; CURRENT APPLICATION NUMBER: US/09/870,574
; CURRENT FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: US 60/169,495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: PCT/US00/14042
; PRIOR FILING DATE: 2000-05-22
; PRIOR APPLICATION NUMBER: PCT/US00/23328
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 2
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Homo Sapien
US-09-870-574-2

Query Match 100.0%; Score 903; DB 4; Length 179;
Best Local Similarity 100.0%; Pred. No. 1.9e-100;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 2
US-09-419-568F-28
; Sequence 28, Application US/09419568F

; Patent No. 6331613
; GENERAL INFORMATION:
; APPLICANT: Dumoutier, Laure
; APPLICANT: Louhed, Jamila
; APPLICANT: Renauld, Jean-Christophe
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules which Encode T Cell Inducible Fac
; TITLE OF INVENTION: (TIFs) The Proteins Encoded, and Uses Thereof
; FILE REFERENCE: LUD 5543.2
; CURRENT APPLICATION NUMBER: US/09/419,568F
; CURRENT FILING DATE: 1999-10-18
; PRIOR APPLICATION NUMBER: US09/354,243
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: US09/178,973
; PRIOR FILING DATE: 1998-10-26
; NUMBER OF SEQ ID NOS: 29
; SEQ ID NO 28
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
US-09-419-568F-28

Query Match 97.6%; Score 881; DB 4; Length 179;
Best Local Similarity 97.8%; Pred. No. 8.3e-98;
Matches 175; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQEGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||:||||||||:||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEILFPQSDRFRPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKCTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 3
US-09-354-243B-28
; Sequence 28, Application US/09354243B
; Patent No. 6359117
; GENERAL INFORMATION:
; APPLICANT: Dumoutier, Laure
; APPLICANT: Louhed, Jamila
; APPLICANT: Renauld, Jean-Christophe
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules which Encode T Cell Inducible Fa
; TITLE OF INVENTION: (TIFs)
; TITLE OF INVENTION: The Proteins Encoded, and Uses Thereof
; FILE REFERENCE: LUD 5543.1
; CURRENT APPLICATION NUMBER: US/09/354,243B
; CURRENT FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: US09/178,973
; PRIOR FILING DATE: 1998-10-26
; NUMBER OF SEQ ID NOS: 29
; SEQ ID NO 28
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
US-09-354-243B-28

Query Match 97.6%; Score 881; DB 4; Length 179;
Best Local Similarity 97.8%; Pred. No. 8.3e-98;
Matches 175; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQEGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||:||||||||:||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEILFPQSDRFRPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKCTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 4
US-09-178-973B-15
; Sequence 15, Application US/09178973B
; Patent No. 6274710
; GENERAL INFORMATION:
; APPLICANT: Dumoutier, Laure
; APPLICANT: Louhed, Jamila
; APPLICANT: Renauld, Jean-Christophe
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules which Encode T Cell Inducible Fa
; TITLE OF INVENTION: (TIFs)
; TITLE OF INVENTION: The Proteins Encoded, and Uses Thereof
; FILE REFERENCE: LUD 5543
; CURRENT APPLICATION NUMBER: US/09/178,973B
; CURRENT FILING DATE: 1998-10-26
; NUMBER OF SEQ ID NOS: 17
; SEQ ID NO 15
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-178-973B-15

Query Match 80.2%; Score 724; DB 3; Length 179;
Best Local Similarity 78.2%; Pred. No. 5.9e-79;
Matches 140; Conservative 19; Mismatches 20; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              || ||||:|  |||||| |||||:||  |   | |::: |:|: |||||||| |||||||
Db          1 MAVLQKSMSFSLMGTLAASCLLLIALWAQEANALPVNTRCKLEVSNFQQPYIVNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              |||||||||||||||||||| |||  ::|||||||||||||:|| ||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFRGVSAKDQCYLMKQVLNFTLEDVLLPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              || :|||:||:||| ||| :||:||::||:|||||||||||||||||||||||||||||:
Db        121 FLTKLSNQLSSCHISGDDQNIQKNVRRLKETVKKLGESGEIKAIGELDLLFMSLRNACV 179
```

RESULT 5
US-09-419-568F-27
; Sequence 27, Application US/09419568F
; Patent No. 6331613
; GENERAL INFORMATION:
; APPLICANT: Dumoutier, Laure
; APPLICANT: Louhed, Jamila
; APPLICANT: Renauld, Jean-Christophe
; TITLE OF INVENTION: Isolated Nucleic Acid Molecules which Encode T Cell Inducible Fac
; TITLE OF INVENTION: (TIFs) The Proteins Encoded, and Uses Thereof
; FILE REFERENCE: LUD 5543.2
; CURRENT APPLICATION NUMBER: US/09/419,568F
; CURRENT FILING DATE: 1999-10-18
; PRIOR APPLICATION NUMBER: US09/354,243
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: US09/178,973
; PRIOR FILING DATE: 1998-10-26
; NUMBER OF SEQ ID NOS: 29
; SEQ ID NO 27
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Mus musculus
; FEATURE:
US-09-419-568F-27

Query Match 80.2%; Score 724; DB 4; Length 179;
Best Local Similarity 78.2%; Pred. No. 5.9e-79;
Matches 140; Conservative 19; Mismatches 20; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              || ||||:|  ||||||  |||||:||  |    | |::: |:|: ||||||||  |||||||
Db          1 MAVLQKSMSFSLMGTLAASCLLLIALWAQEANALPVNTRCKLEVSNFQQPYIVNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              |||||||||||||||||||| |||  ::|||||||||||||:|| ||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFRGVSAKDQCYLMKQVLNFTLEDVLLPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              || :|||:||:||| ||| :||:||::||:|||||||||||||||||||||||||||:
Db        121 FLTKLSNQLSSCHISGDDQNIQKNVRRLKETVKKLGESGEIKAIGELDLLFMSLRNACV 179


RESULT 6
US-09-354-243B-27
; Sequence 27, Application US/09354243B
; Patent No. 6359117
; GENERAL INFORMATION:
;  APPLICANT:  Dumoutier, Laure
;  APPLICANT:  Louhed, Jamila
;  APPLICANT:  Renauld, Jean-Christophe
;  TITLE OF INVENTION:  Isolated Nucleic Acid Molecules which Encode T Cell Inducible Fa
;  TITLE OF INVENTION:  (TIFs)
;  TITLE OF INVENTION:  The Proteins Encoded, and Uses Thereof
;  FILE REFERENCE:  LUD 5543.1
;  CURRENT APPLICATION NUMBER: US/09/354,243B
;  CURRENT FILING DATE:  1999-07-16
;  PRIOR APPLICATION NUMBER:  US09/178,973
;  PRIOR FILING DATE:  1998-10-26
;  NUMBER OF SEQ ID NOS:  29
; SEQ ID NO 27
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Mus musculus
;   FEATURE:
US-09-354-243B-27

  Query Match             80.2%;  Score 724;  DB 4;  Length 179;
  Best Local Similarity   78.2%;  Pred. No. 5.9e-79;
  Matches  140;  Conservative   19;  Mismatches   20;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              || ||||:|  ||||||  |||||:||  |    | |::: |:|: ||||||||  |||||||
Db          1 MAVLQKSMSFSLMGTLAASCLLLIALWAQEANALPVNTRCKLEVSNFQQPYIVNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              |||||||||||||||||||| |||  ::|||||||||||||:|| ||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFRGVSAKDQCYLMKQVLNFTLEDVLLPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              || :|||:||:||| ||| :||:||::||:|||||||||||||||||||||||||||:
Db        121 FLTKLSNQLSSCHISGDDQNIQKNVRRLKETVKKLGESGEIKAIGELDLLFMSLRNACV 179


RESULT 7
US-09-178-973B-16
; Sequence 16, Application US/09178973B
; Patent No. 6274710
; GENERAL INFORMATION:
;  APPLICANT: Dumoutier, Laure
;  APPLICANT:  Louhed, Jamila
;  APPLICANT:  Renauld, Jean-Christophe
;  TITLE OF INVENTION: Isolated Nucleic Acid Molecules which Encode T Cell Inducible Fac
;  TITLE OF INVENTION:  (TIFs)
;  TITLE OF INVENTION:  The Proteins Encoded, and Uses Thereof
;  FILE REFERENCE: LUD 5543
;  CURRENT APPLICATION NUMBER: US/09/178,973B
;  CURRENT FILING DATE:  1998-10-26
;  NUMBER OF SEQ ID NOS: 17
; SEQ ID NO 16
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Mus musculus
US-09-178-973B-16

  Query Match             79.7%;  Score 720;  DB 3;  Length 179;
  Best Local Similarity   77.7%;  Pred. No. 1.8e-78;
  Matches  139;  Conservative   20;  Mismatches   20;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              || ||||:|  ||||||  |||||:||  |    | ||:: |:|: ||||||||  |||||||
Db          1 MAVLQKSMSFSLMGTLAASCLLLIALWAQEANALPINTRCKLEVSNFQQPYIVNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              |||||||||||||||||||| |||  ::|||||||||||||::| ||||||:||||||||
Db         61 KEASLADNNTDVRLIGEKLFRGVSAKDQCYLMKQVLNFTLEDILLPQSDRFRPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              || :|||:||:||| ||| :||:||::||:|||||||||||||||||||||||||||:
Db        121 FLTKLSNQLSSCHISGDDQNIQKNVRRLKETVKKLGESGEIKAIGELDLLFMSLRNACV 179


RESULT 8
US-08-270-805C-2
; Sequence 2, Application US/08270805C
; Patent No. 5776451
;  GENERAL INFORMATION:
;    APPLICANT:  Di-Hwei Hsu
;    APPLICANT:  Kevin K. Moore
;    APPLICANT:  Hergen Spits
;    TITLE OF INVENTION:  Use of Interleukin10 in Adoptive Immunotherapy
;    TITLE OF INVENTION:  of Cancer
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schering-Plough Corporation
;      STREET:  2000 Galloping Hill Road
;      CITY:  Kenilworth
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07033
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  Macintosh
;      OPERATING SYSTEM:  7.5.3
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/270,805C
;      FILING DATE:  05-July-1994
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/995,564
;      FILING DATE:  23-Dec-1992
;      APPLICATION NUMBER:  US 07/830,493
;      FILING DATE:  04-Feb-1992
;      APPLICATION NUMBER:  US 07/641,342
;      FILING DATE:  16-Jan-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Foulke, Cynthia L.
;      REGISTRATION NUMBER:  32,364
;      REFERENCE/DOCKET NUMBER:  DX0142Q2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  908-298-2987
;      TELEFAX:  908-298-5388
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  170 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-270-805C-2

  Query Match             12.1%;  Score 109;  DB 1;  Length 170;
  Best Local Similarity   26.7%;  Pred. No. 3.7e-05;
  Matches   43;  Conservative   24;  Mismatches   68;  Indels   26;  Gaps    6;
```

```
Qy          20 CLLLLALLVQGGAAAPISSHCRLDKSNFQQ-------PYITNRTFMLAKEASLADNNTDV 72
               ||:|| |  : |     :  |     || |        :   :||   |:        |
Db          11 CLVLLYLAPECGG----TDQC----DNFPQMLRDLRDAFSRVKTFFQTKD------EVDN 56

Qy          73 RLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLAR----LSNR 128
                 |: | |         |  : ::: | ||||: ||::   |  :: |  |       | |
Db          57 LLLKESLLEDFKGYLGCQALSEMIQFYLEEVM-PQAENQDPEAKDHVNSLGENLKTLRLR 115

Qy         129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
               |  ||      :  : |:::|:   || | |  ||: | |:
Db         116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156


RESULT 9
US-08-410-654B-2
; Sequence 2, Application US/08410654B
; Patent No. 5833976
;  GENERAL INFORMATION:
;    APPLICANT:  Rene de Waal Malefyt
;    APPLICANT:  Di-Hwei Hsu
;    APPLICANT:  Anne O'Garra
;    APPLICANT:  Hergen Spits
;    TITLE OF INVENTION:  Use of Interleukin-10 to Treat
;    TITLE OF INVENTION:  Septic Shock
;    NUMBER OF SEQUENCES:  61
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schering-Plough Corporation
;      STREET:  2000 Galloping Hill Road
;      CITY:  Kenilworth
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07033
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  Macintosh
;      OPERATING SYSTEM:  7.5.3
;      SOFTWARE:  Microsoft Word 5.1a
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/410,654B
;      FILING DATE:  24-MAR-1995
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/229,854
;      FILING DATE:  19-APR-1994
;      APPLICATION NUMBER:  US 07/926,853
;      FILING DATE:  06-AUG-1992
;      APPLICATION NUMBER:  US 07/742,129
;      FILING DATE:  06-AUG-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Foulke, Cynthia L.
;      REGISTRATION NUMBER:  32,364
;      REFERENCE/DOCKET NUMBER:  DX0221KQ1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  908-298-2987
;      TELEFAX:  908-298-5388
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  170 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-410-654B-2

  Query Match             12.1%;  Score 109;  DB 2;  Length 170;
  Best Local Similarity   26.7%;  Pred. No. 3.7e-05;
  Matches   43;  Conservative   24;  Mismatches   68;  Indels   26;  Gaps    6;

Qy          20 CLLLLALLVQGGAAAPISSHCRLDKSNFQQ-------PYITNRTFMLAKEASLADNNTDV 72
               ||:|| |  : |     :  |     || |        :   :||   |:        |
Db          11 CLVLLYLAPECGG----TDQC----DNFPQMLRDLRDAFSRVKTFFQTKD------EVDN 56

Qy          73 RLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLAR----LSNR 128
                 |: | |         |  : ::: | ||||: ||::   |  :: |  |       | |
Db          57 LLLKESLLEDFKGYLGCQALSEMIQFYLEEVM-PQAENQDPEAKDHVNSLGENLKTLRLR 115

Qy         129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
               |  ||      :  : |:::|:   || | |  ||: | |:
Db         116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156


RESULT 10
US-08-474-851-2
; Sequence 2, Application US/08474851
; Patent No. 5837232
;  GENERAL INFORMATION:
;    APPLICANT:  Rene de Waal Malefyt
;    APPLICANT:  Di-Hwei Hsu
;    APPLICANT:  Anne O'Garra
;    APPLICANT:  Hergen Spits
;    TITLE OF INVENTION:  Use of An Interleukin-10 Antagonist to Treat
;    TITLE OF INVENTION:  A B Cell Mediated Autoimmune Disorder
;    NUMBER OF SEQUENCES:  61
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schering-Plough Corporation
;      STREET:  2000 Galloping Hill Road
;      CITY:  Kenilworth
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07033
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  Macintosh
;      OPERATING SYSTEM:  7.5.3
;      SOFTWARE:  Microsoft Word 6.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/474,851
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/410,654
;      FILING DATE:  24-MAR-1995
;      APPLICATION NUMBER:  US 08/229,854
;      FILING DATE:  19-APR-1994
;      APPLICATION NUMBER:  US 07/926,853
;      FILING DATE:  06-AUG-1992
;      APPLICATION NUMBER:  US 07/742,129
;      FILING DATE:  06-AUG-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Foulke, Cynthia L.
;      REGISTRATION NUMBER:  32,364
;      REFERENCE/DOCKET NUMBER:  DX0221KQ1GD
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  908-298-2987
;      TELEFAX:  908-298-5388
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  170 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-474-851-2

  Query Match             12.1%;  Score 109;  DB 2;  Length 170;
  Best Local Similarity   26.7%;  Pred. No. 3.7e-05;
  Matches   43;  Conservative   24;  Mismatches   68;  Indels   26;  Gaps    6;

Qy          20 CLLLLALLVQGGAAAPISSHCRLDKSNFQQ-------PYITNRTFMLAKEASLADNNTDV 72
               ||:|| |  : |     :  |     || |        :   :||   |:        |
Db          11 CLVLLYLAPECGG----TDQC----DNFPQMLRDLRDAFSRVKTFFQTKD------EVDN 56

Qy          73 RLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLAR----LSNR 128
                 |: | |         |  : ::: | ||||: ||::   |  :: |  |       | |
Db          57 LLLKESLLEDFKGYLGCQALSEMIQFYLEEVM-PQAENQDPEAKDHVNSLGENLKTLRLR 115

Qy         129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
               |  ||      :  : |:::|:   || | |  ||: | |:
Db         116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156
```

```
Qy        129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
              |  ||      :  : |:::|:   || | |  ||: | |:
Db        116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156


RESULT 11
US-08-481-560-2
; Sequence 2, Application US/08481560
; Patent No. 5837293
;  GENERAL INFORMATION:
;    APPLICANT:  Rene de Waal Malefyt
;    APPLICANT:  Di-Hwei Hsu
;    APPLICANT:  Anne O'Garra
;    APPLICANT:  Hergen Spits
;    TITLE OF INVENTION:  Use of Interleukin-10 to Modulate
;    TITLE OF INVENTION:  Inflammation or T-Cell Mediated
;    TITLE OF INVENTION:  Immune Function
;    NUMBER OF SEQUENCES:  61
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schering-Plough Corporation
;      STREET:  2000 Galloping Hill Road
;      CITY:  Kenilworth
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07033
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  Macintosh
;      OPERATING SYSTEM:  7.5.3
;      SOFTWARE:  Microsoft Word 6.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/481,560
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/410,654
;      FILING DATE:  24-MAR-1995
;      APPLICATION NUMBER:  US 08/229,854
;      FILING DATE:  19-APR-1994
;      APPLICATION NUMBER:  US 07/926,853
;      FILING DATE:  06-AUG-1992
;      APPLICATION NUMBER:  US 07/742,129
;      FILING DATE:  06-AUG-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Foulke, Cynthia L.
;      REGISTRATION NUMBER:  32,364
;      REFERENCE/DOCKET NUMBER:  DX0221KQ1GC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  908-298-2987
;      TELEFAX:  908-298-5388
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  170 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-481-560-2

  Query Match             12.1%;  Score 109;  DB 2;  Length 170;
  Best Local Similarity   26.7%;  Pred. No. 3.7e-05;
  Matches   43;  Conservative   24;  Mismatches   68;  Indels   26;  Gaps    6;

Qy         20 CLLLLALLVQGGAAAPISSHCRLDKSNFQQ-------PYITNRTFMLAKEASLADNNTDV 72
              ||:|| |  : |      :  |     || |         :   :||    |:        |
Db         11 CLVLLYLAPECGG----TDQC----DNFPQMLRDLRDAFSRVKTFFQTKD------EVDN 56

Qy         73 RLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLAR----LSNR 128
               |: | |          |  : ::: | ||||: ||::    |  :: |  |       |  |
Db         57 LLLKESLLEDFKGYLGCQALSEMIQFYLEEVM-PQAENQDPEAKDHVNSLGENLKTLRLR 115

Qy        129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
              |  ||      :  : |:::|:   || | |  ||: | |:
Db        116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156


RESULT 12
US-08-934-959-4
; Sequence 4, Application US/08934959
; Patent No. 5989867
;  GENERAL INFORMATION:
;    APPLICANT:  Knappe, Andrea
;    APPLICANT:  Fickenscher, Helmut
;    APPLICANT:  Fleckenstein, Bernhard
;    TITLE OF INVENTION:  MAMMALIAN CYTOKINE; RELATED REAGENTS
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DNAX Research Institute
;      STREET:  901 California Avenue
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94304-1104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/934,959
;      FILING DATE:  22-SEP-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/027,368
;      FILING DATE:  23-SEP-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ching, Edwin P.
;      REGISTRATION NUMBER:  34,090
;      REFERENCE/DOCKET NUMBER:  DX0644K
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-852-9196
;      TELEFAX:  650-496-1200
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  170 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  not relevant
;      TOPOLOGY:  not relevant
;    MOLECULE TYPE:  peptide
US-08-934-959-4

  Query Match             12.1%;  Score 109;  DB 2;  Length 170;
  Best Local Similarity   26.7%;  Pred. No. 3.7e-05;
  Matches   43;  Conservative   24;  Mismatches   68;  Indels   26;  Gaps    6;

Qy         20 CLLLLALLVQGGAAAPISSHCRLDKSNFQQ-------PYITNRTFMLAKEASLADNNTDV 72
              ||:|| |  : |      :  |     || |         :   :||    |:        |
Db         11 CLVLLYLAPECGG----TDQC----DNFPQMLRDLRDAFSRVKTFFQTKD------EVDN 56

Qy         73 RLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLAR----LSNR 128
               |: | |          |  : ::: | ||||: ||::    |  :: |  |       |  |
Db         57 LLLKESLLEDFKGYLGCQALSEMIQFYLEEVM-PQAENQDPEAKDHVNSLGENLKTLRLR 115

Qy        129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
              |  ||      :  : |:::|:   || | |  ||: | |:
Db        116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156


RESULT 13
US-08-170-113-2
; Sequence 2, Application US/08170113
; Patent No. 6106823
;  GENERAL INFORMATION:
;    APPLICANT:  Vieira, Paulo J.
;    APPLICANT:  Moore, Kevin W.
;    APPLICANT:  de Waal Malefyt, Rene
```

```
;    APPLICANT:  de Vries, Jan E.
;    APPLICANT:  Fluckinger, Anne-Catherine
;    APPLICANT:  Banchereau, Jacques
;    TITLE OF INVENTION:  TREATMENT OF NEOPLASTIC DISEASE WITH
;    TITLE OF INVENTION:  INTERLEUKIN-10
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DNAX Research Institute
;      STREET:  901 California Avenue
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94304-1104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/170,113
;      FILING DATE:  17-DEC-1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/933,419
;      FILING DATE:  21-AUG-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/091,333
;      FILING DATE:  12-JUL-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/020,018
;      FILING DATE:  17-FEB-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/830,496
;      FILING DATE:  04-FEB-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/641,347
;      FILING DATE:  16-JAN-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ching, Edwin P.
;      REGISTRATION NUMBER:  34,090
;      REFERENCE/DOCKET NUMBER:  DX0116Q1KX
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-852-9196
;      TELEFAX:  415-496-1200
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  170 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-170-113-2

  Query Match             12.1%;  Score 109;  DB 3;  Length 170;
  Best Local Similarity   26.7%;  Pred. No. 3.7e-05;
  Matches   43;  Conservative   24;  Mismatches   68;  Indels   26;  Gaps    6;

Qy         20 CLLLLALLVQGGAAAPISSHCRLDKSNFQQ-------PYITNRTFMLAKEASLADNNTDV 72
              ||:|| |  : |     :  |     || |        :   :||   |:        |
Db         11 CLVLLYLAPECGG----TDQC----DNFPQMLRDLRDAFSRVKTFFQTKD------EVDN 56

Qy         73 RLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLAR----LSNR 128
              |: | |          |  : ::: | ||||: ||::   |  :: | |       | |
Db         57 LLLKESLLEDFKGYLGCQALSEMIQFYLEEVM-PQAENQDPEAKDHVNSLGENLKTLRLR 115

Qy        129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
              |  ||      :  : |:::|:   || | |  ||: | |:
Db        116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156


RESULT 14
US-08-765-094C-26
; Sequence 26, Application US/08765094C
; Patent No. 6159937
;  GENERAL INFORMATION:
;    APPLICANT:  GRONHOJ LARSEN, Christian
;    APPLICANT:  GESSER, Borbala
;    TITLE OF INVENTION:  IMMUNOMODULATORS
;    NUMBER OF SEQUENCES:  27
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BROWDY AND NEIMARK, P.L.L.C.
;      STREET:  419 Seventh Street N.W., Suite 300
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/765,094C
;      FILING DATE:  06-JAN-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/DK95/00227
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0800/94
;      FILING DATE:  05-JUL-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  COOPER, Iver P.
;      REGISTRATION NUMBER:  28,005
;      REFERENCE/DOCKET NUMBER:  GRONHOJ-LARSEN=1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)628-5197
;      TELEFAX:  (202)737-3528
;  INFORMATION FOR SEQ ID NO:  26:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  170 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-765-094C-26

  Query Match             12.1%;  Score 109;  DB 3;  Length 170;
  Best Local Similarity   26.7%;  Pred. No. 3.7e-05;
  Matches   43;  Conservative   24;  Mismatches   68;  Indels   26;  Gaps    6;

Qy         20 CLLLLALLVQGGAAAPISSHCRLDKSNFQQ-------PYITNRTFMLAKEASLADNNTDV 72
              ||:|| |  : |     :  |     || |        :   :||   |:        |
Db         11 CLVLLYLAPECGG----TDQC----DNFPQMLRDLRDAFSRVKTFFQTKD------EVDN 56

Qy         73 RLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLAR----LSNR 128
              |: | |          |  : ::: | ||||: ||::   |  :: | |       | |
Db         57 LLLKESLLEDFKGYLGCQALSEMIQFYLEEVM-PQAENQDPEAKDHVNSLGENLKTLRLR 115

Qy        129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
              |  ||      :  : |:::|:   || | |  ||: | |:
Db        116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156


RESULT 15
US-09-082-797-26
; Sequence 26, Application US/09082797
; Patent No. 6168791
;  GENERAL INFORMATION:
;    APPLICANT:  GRONHOJ LARSEN, Christian
;    APPLICANT:  GESSER, Borbala
;    TITLE OF INVENTION:  IMMUNOMODULATORS
;    NUMBER OF SEQUENCES:  27
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BROWDY AND NEIMARK, P.L.L.C.
;      STREET:  419 Seventh Street N.W., Suite 300
;      CITY:  Washington
```

```
;       STATE:  D.C.
;       COUNTRY:  U.S.A.
;       ZIP:  20004
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/082,797
;       FILING DATE:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/765,094
;       FILING DATE:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  DK 0800/94
;       FILING DATE:  05-JUL-1994
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  COOPER, Iver P.
;       REGISTRATION NUMBER:  28,005
;       REFERENCE/DOCKET NUMBER:  GRONHOJ-LARSEN=1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (202)628-5197
;       TELEFAX:  (202)737-3528
;   INFORMATION FOR SEQ ID NO:  26:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  170 amino acids
;       TYPE:  amino acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  peptide
US-09-082-797-26

  Query Match             12.1%;  Score 109;  DB 3;  Length 170;
  Best Local Similarity   26.7%;  Pred. No. 3.7e-05;
  Matches   43;  Conservative   24;  Mismatches   68;  Indels   26;  Gaps    6;

Qy         20 CLLLLALLVQGGAAAPISSHCRLDKSNFQQ-------PYITNRTFMLAKEASLADNNTDV 72
              ||:|| |  : |     :  |     || |        :   :||   |:        |
Db         11 CLVLLYLAPECGG----TDQC----DNFPQMLRDLRDAFSRVKTFFQTKD------EVDN 56

Qy         73 RLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVPFLAR----LSNR 128
              |: | |          |  : ::: | ||||: ||::   |  :: |  |      |  |
Db         57 LLLKESLLEDFKGYLGCQALSEMIQFYLEEVM-PQAENQDPEAKDHVNSLGENLKTLRLR 115

Qy        129 LSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDL 169
              |  ||      :  : |:::|:   || | |  ||: | |:
Db        116 LRRCHRFLPCENKSKAVEQIKNAFNKLQEKGIYKAMSEFDI 156


Search completed: December  5, 2003, 18:21:31
Job time : 29.64 secs
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: December 5, 2003, 16:39:13 ; Search time 58.9323 Seconds
(without alignments)
482.113 Million cell updates/sec

Title: US-10-084-298-2
Perfect score: 903
Sequence: 1 MAALQKSVSSFLMGTLATSC.....EIKAIGELDLLFMSLRNACI 179

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	903	100.0	179	21	AAB36292	Human GIL-19/AE289
2	903	100.0	179	21	AAY92879	Human T cell induc
3	903	100.0	179	22	AAE04538	Human cytokine, ZC
4	903	100.0	179	22	AAB62664	Human IL-TIF polyp
5	903	100.0	179	22	AAB87602	Human PRO10096. H
6	903	100.0	179	22	AAB31210	Amino acid sequenc
7	903	100.0	179	22	AAB48074	Human extracellula
8	903	100.0	179	23	AAE28608	Human IL-TIF prote
9	903	100.0	179	23	ABB79910	Human interleukin-
10	903	100.0	179	23	ABG95927	Human secreted/tra
11	903	100.0	179	23	ABB95599	Human angiogenesis
12	903	100.0	179	23	AAU76909	Human interleukin-
13	903	100.0	179	23	AAU78081	Human interleukin
14	903	100.0	179	23	ABB84993	Human PRO10096 pro
15	903	100.0	179	23	AAE19237	Human TIF protein.
16	903	100.0	179	23	AAU83713	Human PRO protein,
17	903	100.0	179	24	ABU71582	Human secreted pol
18	903	100.0	179	24	ABU72028	Novel human secret
19	903	100.0	179	24	ABU72067	Novel human secret
20	903	100.0	179	24	ABU72185	Human PRO polypept
21	903	100.0	179	24	ABU67168	Novel human secret
22	903	100.0	179	24	ABU67299	Novel human secret
23	903	100.0	179	24	AAE30833	Human interleukin-
24	899	99.6	179	22	AAB37122	Human interleukin-
25	881	97.6	179	22	AAU09091	Human T cell deriv
26	881	97.6	179	23	AAE16554	Human T cell deriv
27	850	94.1	167	22	AAE04539	Human cytokine, ZC
28	724	80.2	179	21	AAY92877	Murine T cell indu
29	724	80.2	179	22	AAU09090	Mouse T cell deriv
30	724	80.2	179	23	ABB79911	Mouse interleukin-
31	724	80.2	179	23	AAE19235	Mouse TIF alpha pr
32	724	80.2	179	23	AAE16553	Mouse T cell deriv
33	721	79.8	179	22	AAE05052	Mouse ZCYTO18 prot
34	720	79.7	179	21	AAY92878	Murine T cell indu
35	720	79.7	179	23	AAE28614	Human IL-TIF prote
36	720	79.7	179	23	AAE19236	Mouse TIF beta pro
37	720	79.7	194	24	AAE30840	Mouse interleukin-
38	148	16.4	29	22	AAE05049	Human ZCYTO18 pept
39	112	12.4	24	22	AAE05051	Human ZCYTO18 pept
40	109	12.1	170	13	AAR26403	Viral IL-10. Synt
41	109	12.1	170	14	AAR32277	Viral interleukin-
42	109	12.1	170	14	AAR41665	Viral Interleukin-
43	109	12.1	170	14	AAR42643	Viral Interleukin
44	109	12.1	170	19	AAW46586	Viral interleukin-
45	109	12.1	170	20	AAW81422	Viral interleukin-

ALIGNMENTS

RESULT 1
AAB36292
ID AAB36292 standard; Protein; 179 AA.
XX
AC AAB36292;
XX
DT 23-FEB-2001 (first entry)
XX
DE Human GIL-19/AE289 protein sequence.
XX
KW Human; GIL-19/AE289; IL-10; interleukin-10; nutrition;
KW cell proliferation; immune stimulation; immune suppression;
KW haematopoiesis regulation; tissue growth; inflammation; cancer.
XX
OS Homo sapiens.
XX
PN WO200065027-A2.
XX
PD 02-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US11479.
XX
PR 28-APR-1999; 99US-0131473.
XX
PA (GEMY) GENETICS INST INC.
XX
PI Jacobs K, Fouser L, Spaulding V, Xuan D;
XX
DR WPI; 2000-687325/67.
DR N-PSDB; AAC81773.
XX
PT Human GIL-19 protein that shows a high degree of homology to IL

PT (interleukin)-10, useful in upregulation of humoral immune responses,
PT as an antiinflammatory agent and as a modulator of immune responses
PT associated with injury -
XX
PS Claim 9; Page 59-60; 60pp; English.
XX
CC The present invention provides the protein and coding sequences for the
CC novel human GIL-19/AE289 protein. The protein shows homology to
CC interleukin-10 (IL-10) and is assumed to be a cytokine. It can be used
CC in the regulation of cell proliferation and differentiation,
CC haematopoiesis, immune stimulation or suppression, tissue growth and
CC tumour inhibition. In addition, it also has uses in the treatment of
CC inflammation and in nutrition.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 21; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
Db 1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy 61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
Db 61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy 121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
Db 121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179

RESULT 2
AAY92879
ID AAY92879 standard; Protein; 179 AA.
XX
AC AAY92879;
XX
DT 04-SEP-2000 (first entry)
XX
DE Human T cell inducible factor.
XX
KW TIF; T cell derived inducible factor; interleukin 9; STAT; IL-9;
KW Anti-asthmatic; anti-allergic; cytostatic; inhibitor; antagonist;
KW chromosome 12q15.
XX
OS Homo sapiens.
XX
PN WO200024758-A1.
XX
PD 04-MAY-2000.
XX
PF 18-OCT-1999; 99WO-US24424.
XX
PR 26-OCT-1998; 98US-0178973.
PR 16-JUL-1999; 99US-0354243.
XX
PA (LUDW-) LUDWIG INST CANCER RES.
XX
PI Dumoutier L, Louhed J, Renauld J;
XX
DR WPI; 2000-422495/36.
DR N-PSDB; AAA28839, AAA28840.
XX
PT New nucleic acid molecule encoding a T cell derived inducible factor
PT for treating asthma, an allergy or lymphoma
XX
PS Example 26; Fig 1; 46pp; English.
XX
CC This is the human T cell derived inducible factor (TIF). The gene
CC was mapped to chromosome 12q15. The human TIF was identified based on
CC homology to a murine TIF, which was identified by subtraction cloning
CC from a murine lymphoma cell line BW5147 in the presence or absence of
CC interleukin 9 (IL-9). BW5147, can be grown in vitro, without the need to
CC add any cytokines to its culture medium. Many IL-9 activities are
CC mediated by activation of STAT transcription factors. The novel TIFs were
CC expressed in the presence of IL-9, but not in its absence. TIFs induce
CC STAT activation in cells. They can be used, e.g. in the stimulation of
CC regeneration of targeted tissues. Their inhibitors or antagonists can be
CC used to retard, prevent or inhibit differentiation of other tissues. The
CC TIFs and their coding sequences are useful in the treatment of asthma,
CC allergies and lymphoma (claimed). They are also useful for identifying
CC compounds that inhibit or activate T cell induced factor activity in a
CC cell (claimed).
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 21; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
Db 1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy 61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
Db 61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy 121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
Db 121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179

RESULT 3
AAE04538
ID AAE04538 standard; Protein; 179 AA.
XX
AC AAE04538;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human cytokine, ZCYTO18 protein #1.
XX
KW Human; cytostatic; cytokine; ZCYTO18 protein; genetic abnormality;
KW cancer; inflammation; gene therapy.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..33
FT /label= Signal_peptide
FT Protein 34..179
FT /label= Mature_ZCYTO18_protein
FT Region 145..150
FT /label= Hydrophilic_region
XX
PN WO200146422-A1.
XX
PD 28-JUN-2001.
XX
PF 22-DEC-2000; 2000WO-US35308.
XX
PR 23-DEC-1999; 99US-0471767.
PR 01-DEC-2000; 2000US-0250841.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Presnell SR, Kindsvogel W;
XX
DR WPI; 2001-408648/43.
DR N-PSDB; AAD09719.
XX
PT Novel human cytokine polypeptide, ZCYTO18, useful for treating cancer -
XX

PS Claim 4; Page 142; 167pp; English.
XX
CC The patent discloses novel human cytokine, ZCYTO18 protein and its
CC corresponding DNA. ZCYTO18 protein induces proliferation of cells
CC expressing zcytor11, a receptor for ZCYTO18 or induces cytotoxicity
CC in K5626 cells. ZCYTO18 DNA is useful for detecting a genetic
CC abnormality in a patient. ZCYTO18 DNA and its antibodies are useful
CC for detecting cancer and inflammation. ZCYTO18 protein is useful for
CC killing cancer cells. It is useful for increasing platelets in a
CC patient or injured tissue. It is also used in gene therapy.
CC The present sequence is novel human cytokine, ZCYTO18 protein.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 22; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 4
AAB62664
ID AAB62664 standard; Protein; 179 AA.
XX
AC AAB62664;
XX
DT 23-JUL-2001 (first entry)
XX
DE Human IL-TIF polypeptide.
XX
KW Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
KW antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
KW immunosuppressive; chromosome 6q24.1-25.2; human.
XX
OS Homo sapiens.
XX
PN WO200140467-A1.
XX
PD 07-JUN-2001.
XX
PF 01-DEC-2000; 2000WO-US32703.
XX
PR 03-DEC-1999; 99US-0169049.
PR 13-SEP-2000; 2000US-0232219.
PR 31-OCT-2000; 2000US-0244610.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Presnell SR, Xu W, Kindsvogel W, Chen Z;
XX
DR WPI; 2001-356158/37.
DR N-PSDB; AAF83741.
XX
PT New soluble cytokine receptor polypeptides and polynucleotides, useful
PT for diagnosing and treating cancer and inflammatory conditions -
XX
PS Example 17; Page 195-196; 210pp; English.
XX
CC The invention relates to a human cytokine receptor polypeptide,
CC designated zcytor16. The zcytor16 polypeptide can be expressed by
CC standard recombinant methodology and can bind to IL-TIF (undefined). The
CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
CC or differentiation of hematopoietic cell(s) (progenitors); reducing
CC IL-TIF induced or IL-9 induced inflammation; and suppressing an
CC inflammatory response in a mammal with inflammation. Heteromeric/
CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
CC can also be used to detect IL-TIF levels which is indicative of
CC pathological conditions including inflammatory states (e.g. rheumatoid
CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
CC polypeptides themselves are useful for the treatment of inflammation,
CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC diseases. The antibodies and zcytor16 polynucleotides are also useful
CC for detecting cancer. The present sequence represents the human IL-TIF
CC protein.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 22; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 5
AAB87602
ID AAB87602 standard; Protein; 179 AA.
XX
AC AAB87602;
XX
DT 15-MAY-2001 (first entry)
XX
DE Human PRO10096.
XX
KW Human; PRO protein; mapping.
XX
OS Homo sapiens.
XX
PN WO200116318-A2.
XX
PD 08-MAR-2001.
XX
PF 24-AUG-2000; 2000WO-US23328.
XX
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 07-DEC-1999; 99US-0169495.
PR 09-DEC-1999; 99US-0170262.
PR 11-JAN-2000; 2000US-0175481.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 01-MAR-2000; 2000WO-US05601.
PR 03-MAR-2000; 2000US-0187202.
PR 25-APR-2000; 2000US-0199397.
PR 22-MAY-2000; 2000WO-US14042.
PR 05-JUN-2000; 2000US-0209832.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi CJ, Gurney AL, Watanabe CK, Wood WI;
XX

```
DR   WPI; 2001-183260/18.
DR   N-PSDB; AAF92134.
XX
PT   Eighty four nucleic acids encoding PRO polypeptides, useful in
PT   molecular biology, including use as hybridization probes, and in
PT   chromosome and gene mapping. -
XX
PS   Claim 12; Fig 154; 278pp; English.
XX
CC   The present sequence is a human PRO polypeptide (secreted and
CC   transmembrane). The PRO protein, and PRO agonists, PRO antagonists or
CC   anti-PRO antibodies are useful for preparation of a medicament useful in
CC   the treatment of a condition which is responsive to the PRO protein,
CC   agonists, antagonists or anti-PRO antibodies. The PRO protein may also be
CC   employed as molecular weight markers for protein electrophoresis. The PRO
CC   coding sequence has applications in molecular biology, including use as
CC   hybridisation probes, and in chromosome and gene mapping.
XX
SQ   Sequence   179 AA;

  Query Match             100.0%;  Score 903;  DB 22;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 2.7e-86;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 6
AAB31210
ID   AAB31210 standard; Protein; 179 AA.
XX
AC   AAB31210;
XX
DT   20-APR-2001  (first entry)
XX
DE   Amino acid sequence of human polypeptide PRO10096.
XX
KW   Human; secreted protein; transmembrane protein; PRO196; PRO444; PRO183;
KW   PRO185; PRO210; PRO215; PRO217; PRO242; PRO288; PRO365; PRO1361; PRO1308;
KW   PRO1183; PRO1272; PRO1419; PRO4999; PRO7170; PRO248; PRO353; PRO1318;
KW   PRO1600; PRO9940; PRO533; PRO301; PRO187; PRO337; PRO1411; PRO4356;
KW   PRO246; PRO265; PRO941; PRO10096; PRO6003; PRO6004; PRO350; PRO2630;
KW   PRO6309; cell death; genetic disorder; transgenic animal; gene therapy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..33
FT                   /note= "signal peptide"
FT   Modified-site   14..20
FT                   /note= "N-myristoylation site"
FT   Modified-site   54..58
FT                   /note= "N-glycosylation site"
FT   Modified-site   68..72
FT                   /note= "N-glycosylation site"
FT   Modified-site   82..88
FT                   /note= "N-myristoylation site"
FT   Modified-site   97..10
FT                   /note= "N-glycosylation site"
XX
PN   WO200077037-A2.
XX
PD   21-DEC-2000.
XX
PF   22-MAY-2000; 2000WO-US14042.
XX
PR   15-JUN-1999;   99US-0139695.
PR   20-JUL-1999;   99US-0145070.
PR   26-JUL-1999;   99US-0145698.
PR   17-AUG-1999;   99US-0149396.
PR   01-SEP-1999;   99WO-US20111.
PR   08-SEP-1999;   99WO-US20594.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28565.
PR   07-DEC-1999;   99US-0169495.
PR   05-JAN-2000; 2000WO-US00219.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05841.
PR   20-MAR-2000; 2000WO-US07377.
PR   30-MAR-2000; 2000WO-US08439.
PR   15-MAY-2000; 2000WO-US13358.
PR   17-MAY-2000; 2000WO-US13705.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein DA,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Gurney AL,  Kljavin IJ,  Mather JP,  Napier MA,  Pan J;
PI   Paoni NF,  Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM;
PI   Wood WI,  Zhang Z;
XX
DR   WPI; 2001-050091/06.
DR   N-PSDB; AAC87053.
XX
PT   Isolated nucleic acid molecule encoding a PRO polypeptide which is a
PT   transmembrane polypeptide is useful for gene therapy and identification
PT   of related polypeptides -
XX
PS   Claim 12; Fig 64; 244pp; English.
XX
CC   The present sequence represents a human secreted and transmembrane
CC   polypeptide. The specification describes human polypeptides, designated
CC   PRO196, PRO444, PRO183, PRO185, PRO210, PRO215, PRO217, PRO242, PRO288,
CC   PRO365, PRO1361, PRO1308, PRO1183, PRO1272, PRO1419, PRO4999, PRO7170,
CC   PRO248, PRO353, PRO1318, PRO1600, PRO9940, PRO533, PRO301, PRO187,
CC   PRO337, PRO1411, PRO4356, PRO246, PRO265, PRO941, PRO10096, PRO6003,
CC   PRO6004, PRO350, PRO2630 and PRO6309. The biological activity of cells
CC   can be modulated with agents that bind to these polypeptides, resulting
CC   in the death of the cells. The polynucleotides encoding these
CC   polypeptides are useful in the recombinant production of the
CC   polypeptides, as a hybridisation probe to screen libraries to isolate
CC   homologous sequences, or to map the gene. They may also be used for
CC   analysing genetic disorders, and to produce transgenic animals which are
CC   useful for the development and screening of therapeutically useful
CC   reagents. The polynucleotides can also be used in gene therapy e.g. to
CC   replace a defective gene.
XX
SQ   Sequence   179 AA;

  Query Match             100.0%;  Score 903;  DB 22;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 2.7e-86;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
```

```
Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 7
AAB48074
ID AAB48074 standard; protein; 179 AA.
XX
AC AAB48074;
XX
DT 19-MAR-2001 (first entry)
XX
DE Human extracellular signaling molecule (EXCS) (ID 5571181CD1).
XX
KW Extracellular signaling molecule; EXCS; anti-inflammatory; human;
KW immunosuppressive; cytostatic; neuroprotective; gastrointestinal;
KW virucide; antibacterial; anti-HIV; human immunodeficiency virus;
KW antiinfertility; cerebroprotective; nootropic; antiulcer; antifungal;
KW anticonvulsant; tranquilizer; neuroleptic; vasotropic; gynecological;
KW keratolytic; protozoacide; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200070049-A2.
XX
PD 23-NOV-2000.
XX
PF 19-MAY-2000; 2000WO-US13975.
XX
PR 19-MAY-1999; 99US-0134949.
PR 15-JUL-1999; 99US-0144270.
PR 30-JUL-1999; 99US-0146700.
PR 04-OCT-1999; 99US-0157508.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Tang YT, Yue H, Lal P, Burford N, Bandman O, Baughn MR;
PI Azimzai Y, Lu DAM, Patterson C;
XX
DR WPI; 2001-025021/03.
DR N-PSDB; AAC84310.
XX
PT New human extracellular signaling nucleic acids and polypeptides useful
PT for diagnosing, treating and preventing infections and
PT gastrointestinal, neurological, reproductive, and
PT autoimmune/inflammatory disorders -
XX
PS Claim 1; Page 94; 114pp; English.
XX
CC The invention provides human extracellular signaling molecules (EXCS)
CC and polynucleotides which identify and encode EXCS. EXCS can be
CC expressed by standard recombinant methodology. The amino acid and nucleic
CC acid sequences of EXCS are useful for diagnosing, treating and
CC preventing infections and gastrointestinal (peptic ulcer, dysphagia,
CC pancreatitis), neurological (e.g. epilepsy, ischemic cerebrovascular
CC disease, stroke), reproductive (infertility, ovulatory defects,
CC endometriosis), autoimmune /inflammatory (actinic keratosis, acquired
CC immunodeficiency syndrome (AIDS), Addison's disease), and cell
CC proliferative disorders including cancers (of the breast, adrenal gland,
CC bone). They may also be used to treat fatal familial insomnia,
CC nutritional and metabolic diseases of the nervous system, myopathies,
CC mental disorders (anxiety, schizophrenia, mood), as well as infections
CC caused by parasites (malaria, leishmania, trypanosoma), viral
CC (adenovirus, coronavirus, flavivirus), bacterial (e.g. pneumococcus,
CC staphylococcus, bacillus), and fungal (aspergillus, blastomyces,
CC dermatophytes) agents. The nucleic acids, polypeptides, antagonists,
CC agonists, pharmaceutical compositions, and antibodies may also be used
CC for treating or preventing disorders associated with increased or
CC decreased expression or activity of EXCS. EXCS polynucleotides may also
CC be used to detect and quantify gene expression in biopsied tissues in
CC which expression of EXCS may be correlated with the disease, to determine
CC presence or excess expression of EXCS, to monitor regulation of EXCS
CC levels during therapeutic intervention, to detect the presence of
CC associated disorders, as targets in microarray, to generate hybridization
CC probes, and to detect differences in gene sequences among normal, carrier
CC or affected individuals. Antibodies may also be used in diagnosing
CC disorders, in monitoring patients being treated with EXCS agonists,
CC antagonists or inhibitors. Sequences AAB48057-B48082 represent the EXCS
CC of the invention.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 22; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 8
AAE28608
ID AAE28608 standard; Protein; 179 AA.
XX
AC AAE28608;
XX
DT 27-DEC-2002 (first entry)
XX
DE Human IL-TIF protein #1.
XX
KW Cytokine receptor; Zcytor16; IL-TIF; autoimmune disease; dermatological;
KW inflammatory disease; inflammatory bowel disease; rheumatoid arthritis;
KW asthma; systemic lupus erythematosus; myasthenia gravis; pancreatitis;
KW diabetes; atherosclerosis; glomerulonephritis; gene therapy; cytostatic;
KW immunosuppressive; nephrotropic; allergy; placental health; abortion;
KW cancer; human.
XX
OS Homo sapiens.
XX
PN WO200270655-A2.
XX
PD 12-SEP-2002.
XX
PF 04-MAR-2002; 2002WO-US06267.
XX
PR 02-MAR-2001; 2001US-273035P.
PR 27-MAR-2001; 2001US-279232P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Presnell SR, Xu W, Kindsvogel W, Chen Z;
XX
DR WPI; 2002-698750/75.
DR N-PSDB; AAD45964.
XX
PT New Zcytor16 polypeptide useful for treating autoimmune or inflammatory
PT diseases, e.g. inflammatory bowel disease, rheumatoid arthritis,
PT asthma, atherosclerosis, cancer or diabetes, or in assessing
PT therapeutic aspects of IL-TIF -
XX
PS Disclosure; Page 197-198; 221pp; English.
XX
CC The invention relates to cytokine receptor designated as mouse Zcytor16
CC which can bind and antagonise the IL-TIF. The Zcytor16 polypeptide is
CC useful in modulating the immune system by binding Zcytor16 ligand, and

CC thus, preventing the binding of the ligand with endogenous Zcytor16
CC receptor. It is useful for studying human inflammation or immune
CC function, or for treating autoimmune or inflammatory diseases such as
CC inflammatory bowel disease, rheumatoid arthritis, asthma, systemic
CC lupus erythematosus, myasthenia gravis or allergy, atherosclerosis,
CC cancer, diabetes, glomerulonephritis or pancreatitis, or in assessing
CC therapeutic aspects of IL-TIF, chemical therapeutics, anti-IL-TIF
CC antibodies, anti-Zcytor16 antibodies or Zcytor16 soluble receptors.
CC Zcytor16 DNA and the anti-mouse Zcytor16 antibody are useful as probes
CC in detecting gene expression and gene structure, such as in the
CC diagnosis and/or prevention of spontaneous abortions or in monitoring
CC placental health and function. It is also used in gene therapy. The
CC present sequence is human IL-TIF protein.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 23; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 9
ABB79910
ID ABB79910 standard; Protein; 179 AA.
XX
AC ABB79910;
XX
DT 05-DEC-2002 (first entry)
XX
DE Human interleukin-22.
XX
KW Interleukin-22; IL-22; human; cytostatic; antiinflammatory;
KW antibacterial; virucide; fungicide; osteopathic; vulnerary;
KW neuroprotective; immunosuppressive; antiarthritic; antidiabetic;
KW antipsoriatic; antiarteriosclerotic; anticholesterolemic;
KW antiallergic; cytokine; adjuvant.
XX
OS Homo sapiens.
XX

FH	Key	Location/Qualifiers
FT	Peptide	1..33
FT		/label= Signal_peptide
FT	Protein	34..179
FT		/label= Mature_protein
FT	Region	50..60
FT		/note= "IL-22 receptor binding motif"
FT	Region	63..81
FT		/note= "IL-22 receptor binding motif"
FT	Region	168..177
FT		/note= "IL-22 receptor binding motif"

XX
PN WO200268476-A2.
XX
PD 06-SEP-2002.
XX
PF 25-FEB-2002; 2002WO-US05684.
XX
PR 23-FEB-2001; 2001US-270823P.
PR 03-APR-2001; 2001US-281353P.
XX
PA (GEMY) GENETICS INST LLC.
XX
PI Jacobs K, Pittman D, Fouser L, Spaulding V, Xuan D;
XX
DR WPI; 2002-698660/75.
DR N-PSDB; ABQ81260.
XX
PT New antibodies that immunologically react with an interleukin 22 (IL
PT 22) protein, useful for treating conditions associated with IL-22
PT activity in humans, e.g. septicemia, multiple sclerosis, ischemia,
PT atherosclerosis, allergies -
XX
PS Claim 6; Page 10; 76pp; English.
XX
CC The present sequence is the protein sequence of human
CC interleukin-22 (IL-22), a cytokine involved in acute phase
CC responses. The invention provides inhibitors of IL-22, especially
CC an antibody which immunologically reacts with an IL-22 protein,
CC and particularly a humanised monoclonal antibody. The anti-IL-22
CC antibody, or other IL-22 modulator, is useful for treating a
CC pathological condition in need of IL-22 modulation, or associated
CC with IL-22 activity in a subject, particularly a human. In
CC particular, these conditions include septicaemia, autoimmune
CC disorders (e.g. arthritis or rheumatoid arthritis, osteoarthritis,
CC multiple sclerosis, myasthenia gravis, inflammatory bowel disease,
CC lupus, diabetes or psoriasis), infectious diseases state (e.g.
CC infection by bacteria, viruses, parasites or fungi), or the
CC regulation of inflammation and acute phase responses (e.g. wound
CC healing process, cholesterol metabolism, oxygen free radical injury,
CC ischemia, atherosclerosis or allergies). Modulators of IL-22
CC activity are also useful for treating inflammatory pathology
CC in the kidney (which is a result of necrosis due to ischemia)
CC or cancer (e.g. renal cell carcinoma), or for remodelling kidney
CC tissue (all claimed). A subject's immune response to an antigen
CC can be enhanced by administering the antigen and an
CC immunogenicity-augmenting amount of IL-22.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 23; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 10
ABG95927
ID ABG95927 standard; Protein; 179 AA.
XX
AC ABG95927;
XX
DT 10-DEC-2002 (first entry)
XX
DE Human secreted/transmembrane protein PRO10096.
XX
KW Human; secreted protein; transmembrane protein; antirheumatic;
KW antiarthritic; osteopathic; sports-related joint problem;
KW articular cartilage defect; osteoarthritis; rheumatoid arthritis.
XX
OS Homo sapiens.
XX
PN US2002119130-A1.
XX

PD 29-AUG-2002.
XX
PF 06-DEC-2001; 2001US-0006867.
XX
PR 29-OCT-1997; 97US-063435P.
PR 29-OCT-1997; 97US-064215P.
PR 22-APR-1998; 98US-082797P.
PR 29-APR-1998; 98US-083495P.
PR 15-MAY-1998; 98US-085579P.
PR 10-JUN-1998; 98US-088811P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088825P.
PR 11-JUN-1998; 98US-088863P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089514P.
PR 16-SEP-1998; 98WO-US19330.
PR 08-MAR-1999; 99WO-US05028.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21194.
PR 22-DEC-1999; 99WO-US30720.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 30-MAR-2000; 2000WO-US08439.
PR 22-MAY-2000; 2000WO-US14042.
PR 02-JUN-2000; 2000WO-US15264.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32378.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2002-731348/79.
DR N-PSDB; ABS74454.
XX
PT New isolated secreted and transmembrane PRO polypeptide useful for
PT modulating biological activity of a cell, or for treating
PT sports-related joint problems, osteoarthritis or rheumatoid arthritis
XX
PS Claim 20; Fig 154; 399pp; English.
XX
CC The invention relates to an isolated secreted and transmembrane PRO
CC polypeptide having 80 % sequence identity to a sequence appearing
CC as ABG95851-ABG95934 or their associated signal peptide, or a sequence of
CC an extracellular domain of the proteins with their associated signal
CC peptide or lacking its associated signal peptide. Also included are
CC the nucleic acids encoding the proteins, vectors, host cells,
CC fusion proteins and antibodies which specifically bind to the proteins.
CC The proteins are useful for detecting a polypeptide designated as A, B, C
CC or D in a sample suspected of containing an A, B, C or D polypeptide,
CC by contacting the sample with a polypeptide designated as E, F, G, H or
CC I (or vice versa) and determining the formation of a A/E, B/F, B/G, C/H
CC or D/I polypeptide conjugate in the sample, where the formation of the
CC conjugate is indicative of the presence of an A, B, C or D polypeptide
CC in the sample, where A is a PRO10272 polypeptide, B is a PRO20110
CC polypeptide, C is a PRO10096 polypeptide, D is a PRO19760 polypeptide,
CC E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040
CC polypeptide, H is a PRO20233 polypeptide and I is a PRO1890
CC polypeptide. The sample comprises a cell suspected of expressing the A,
CC B, C or D polypeptide. The E, F, G, H or I polypeptide is labeled with
CC a detectable label or is attached to a solid support. The proteins are
CC useful for linking a bioactive molecule to a cell expressing a
CC polypeptide designated as A, B, C or D or E, F, G, H or I. The bioactive
CC molecule is a toxin, a radiolabel or an antibody. The bioactive molecule
CC causes death of the cell. A, B, C, D, E, F, G, H, or I, or antibodies
CC against them are useful for modulating a biological activity of a cell
CC expressing a polypeptide designated as A, B, C or D or E, F, G, H, or
CC I. The cell is killed. The proteins are useful for identifying
CC agonists or antagonists, for the preparation of a medicament useful in
CC the treatment of a condition which is responsive to the proteins, as
CC molecular weight markers for protein electrophoresis purposes, and as
CC therapeutic agents for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis or rheumatoid arthritis.
CC Nucleic acids encoding the proteins are useful as hybridisation probes,
CC in chromosome and gene mapping, in the generation of anti-sense RNA and
CC DNA, for the preparation of the proteins, to generate transgenic or
CC knockout animals which are useful in the development and screening of
CC therapeutic useful reagents, for chromosome identification, and in gene
CC therapy. The antibody is useful as a therapeutic agent, in a diagnostic
CC assay and for affinity purification of the protein from recombinant
CC cell culture natural sources. The present sequence represents a novel
CC secreted or transmembrane protein of the invention.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 23; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 11
ABB95599
ID ABB95599 standard; Protein; 179 AA.
XX
AC ABB95599;
XX
DT 19-JUL-2002 (first entry)
XX
DE Human angiogenesis related protein PRO10096 SEQ ID NO: 354.
XX
KW Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW antiarteriosclerotic.
XX
OS Homo sapiens.
XX
PN WO200208284-A2.
XX
PD 31-JAN-2002.
XX
PF 09-JUL-2001; 2001WO-US21735.
XX
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220664P.
PR 28-JUL-2000; 2000WO-US20710.
PR 02-AUG-2000; 2000US-222695P.
PR 17-AUG-2000; 2000US-0643657.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 07-SEP-2000; 2000US-230978P.
PR 15-SEP-2000; 2000US-000000P.

PR 18-SEP-2000; 2000US-0664610.
PR 18-SEP-2000; 2000US-0665350.
PR 24-OCT-2000; 2000US-242922P.
PR 08-NOV-2000; 2000US-0709238.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 22-JAN-2001; 2001US-0767609.
PR 28-FEB-2001; 2001US-0796498.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 25-MAY-2001; 2001WO-US17092.
PR 30-MAY-2001; 2001US-0870574.
PR 30-MAY-2001; 2001WO-US17443.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 28-JUN-2001; 2001WO-US00000.
XX
PA (GETH) GENENTECH INC.
PA (BAKE/) BAKER K P.
PA (FERR/) FERRARA N.
PA (GERB/) GERBER H.
PA (GERR/) GERRITSEN M E.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P J.
PA (GURN/) GURNEY A L.
PA (HILL/) HILLAN K J.
PA (MARS/) MARSTERS S A.
PA (PANJ/) PAN J.
PA (PAON/) PAONI N F.
PA (STEP/) STEPHAN J F.
PA (WATA/) WATANABE C K.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-171999/22.
DR N-PSDB; ABL95737.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal -
XX
PS Claim 11; Fig 354; 567pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The present sequence is a PRO protein of the invention.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 23; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 12
AAU76909
ID AAU76909 standard; Protein; 179 AA.
XX
AC AAU76909;
XX
DT 05-JUN-2002 (first entry)
XX
DE Human interleukin-T-cell inducible factor (IL-TIF).
XX
KW Z-Cytor II; human; cytokine receptor; atopy; psoriasis;
KW interleukin-T-cell inducible factor; IL-TIF; allergy; asthma;
KW receptor-modulated apoptosis; Th1; immune response; pancreatitis;
KW type I diabetes; IDDM; pancreatic cancer; Graves disease; SLE;
KW inflammatory bowel disease; IBD; Crohn's disease; colon cancer;
KW intestinal cancer; diverticulosis; autoimmune disease; sepsis;
KW multiple sclerosis; MS; systemic lupus erythematosus;
KW myasthaenia gravis; rheumatoid arthritis; kidney dysfunction.
XX
OS Homo sapiens.
XX
PN WO200212345-A2.
XX
PD 14-FEB-2002.
XX
PF 08-AUG-2001; 2001WO-US24838.
XX
PR 08-AUG-2000; 2000US-223827P.
PR 01-DEC-2000; 2000US-250876P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Kindsvogel WR, Topouzis S;
XX
DR WPI; 2002-217182/27.
DR N-PSDB; ABK10503.
XX
PT New soluble cytokine receptor which binds interleukin-T-cell inducible
PT factor and antagonizes its activity in inflammatory and immune diseases
PT such as cancer, diabetes, asthma, sepsis, psoriasis and autoimmune
PT diseases -
XX
PS Example 1; Page 98; 117pp; English.
XX
CC This invention relates to the protein and cDNA sequences of a novel
CC soluble cytokine receptor polypeptide designated zcytorII, which binds
CC interleukin-T-cell inducible factor (IL-TIF) or antagonises IL-TIF
CC activity. The protein of the invention is useful for reducing IL-TIF-
CC or IL-9 induced inflammation, and inhibiting IL-TIF-induced
CC proliferation. The protein is also useful for suppressing an immune
CC response in a mammal exposed to an antigen or pathogen. Soluble zcytorII
CC receptor or heterodimeric polypeptide is useful for enhancing the in
CC vivo killing of target tissues by directly stimulating a zcytorII
CC receptor-modulated apoptotic pathway. IL-TIF is involved in promoting
CC Th1-type immune responses and antagonists of IL-TIF have beneficial use
CC against diseases involving such immune responses. Soluble zcytorII
CC heterodimers are useful as antagonists in inflammatory and immune
CC diseases or conditions such as pancreatitis, type I diabetes (IDDM),
CC pancreatic cancer, Graves disease, inflammatory bowel disease (IBD),
CC Crohn's disease, colon and intestinal cancer, diverticulosis, autoimmune

```
CC   disease (e.g. IDDM, multiple sclerosis (MS), systemic lupus
CC   erythematosus (SLE), myasthaenia gravis, rheumatoid arthritis and IBD),
CC   sepsis, asthma,allergy and other atopic diseases, psoriasis and kidney
CC   dysfunction. Soluble zcytorII receptor or heterodimeric receptor
CC   polypeptides are useful in vivo or in diagnostic applications to detect
CC   IL-TIF expressing cancers in vivo or in tissue samples and to prepare
CC   antibodies. ZcytoRII serves as a target for MAb therapy of cancer where
CC   an antagonising MAb inhibits cancer growth and targets immune-mediated
CC   killing. The present sequence represents the interleukin-T-cell
CC   inducible factor (IL-TIF) protein, the activity of this protein is
CC   inhibited by the ZcytoRII protein of the invention.
XX
SQ   Sequence   179 AA;

  Query Match            100.0%;  Score 903;  DB 23;  Length 179;
  Best Local Similarity  100.0%;  Pred. No. 2.7e-86;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 13
AAU78081
ID   AAU78081 standard; Protein; 179 AA.
XX
AC   AAU78081;
XX
DT   05-JUN-2002  (first entry)
XX
DE   Human interleukin 22 (IL-22) protein sequence.
XX
KW   Interleukin 22; IL-22; cytostatic; antiinflammatory; IL-22 antagonist;
KW   immunotherapy; PAP1; pancreatitis associated protein; receptor;
KW   IL-22R; IL-10Rbeta; bioactive molecule linkage; cell death; pancreatitis;
KW   pancreatic disorder; pancreatic carcinoma; acinar cell carcinoma; human;
KW   mixed cell population pancreatic carcinoma.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide          1..33
FT                    /label= Signal_peptide
FT   Modified-site    14..20
FT                    /note= "Asn is N-myristolated"
FT   Protein          34..179
FT                    /label= Mature_human_interleukin_22_(IL_22)
FT   Modified-site    54..58
FT                    /note= "Asn is N-glycosylated"
FT   Modified-site    68..72
FT                    /note= "Asn is N-glycosylated"
FT   Modified-site    82..88
FT                    /note= "Asn is N-myristolated"
FT   Modified-site    97..101
FT                    /note= "Asn is N-glycosylated"
XX
PN   WO200216611-A2.
XX
PD   28-FEB-2002.
XX
PF   30-MAY-2001; 2001WO-US17443.
XX
PR   24-AUG-2000; 2000WO-US23328.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Aggarwal S,  Foster JS,  Goddard A,  Gurney AL,  Maruoka EM,  Wood WI;
PI   Xie M;
XX
DR   WPI; 2002-280940/32.
DR   N-PSDB; ABK11847.
XX
PT   Novel isolated interleukin 22 polypeptide useful for identifying IL-22
PT   agonists and antagonists that are used for treating acute pancreatitis,
PT   chronic pancreatitis, pancreatic carcinoma  -
XX
PS   Claim 11; Fig 2; 94pp; English.
XX
CC   The present invention relates to a new polypeptide having at least 80%
CC   identity to a 101 amino acid interleukin (IL)-22 sequence. The invention
CC   is useful for detecting IL-22R (IL-22 receptor) or IL-10Rbeta polypeptide
CC   in a sample which involves contacting sample with an IL-22 polypeptide
CC   and determining the formation of an IL-22R/IL-22 polypeptide conjugate or
CC   an IL-10Rbeta/IL-22 polypeptide conjugate. Preferably, the IL-22
CC   polypeptide is labelled with a detectable label or is attached to a solid
CC   support. The polypeptide is also useful for linking a bioactive molecule,
CC   e.g. toxin, radiolabel or antibody that causes the death of the cell, to
CC   a cell expressing IL-22R polypeptide or IL-10Rbeta polypeptide which
CC   involves contacting the cell with IL-22 polypeptide that is bound to the
CC   bioactive molecule and allowing binding of the IL-22 polypeptide with
CC   IL-22R or IL-10Rbeta polypeptide thus linking the bioactive molecules to
CC   the cell. The molecules of the invention can also be used for modulating
CC   biological activity of cell expressing IL-22R or IL-10Rbeta polypeptide,
CC   whereby the cell is killed and the antibody of the invention is useful
CC   for inhibiting IL-22 induced expression of PAP1 (pancreatitis associated
CC   protein) by pancreatic cells. The antibody is also useful for treating a
CC   pancreatic disorder such as acute or chronic pancreatitis, pancreatic
CC   carcinoma including acinar cell carcinoma or mixed cell population
CC   pancreatic carcinoma and for reducing the activated or inflamed condition
CC   of the pancreas in a mammal. The present amino acid sequence represents
CC   the human interleukin 22 (IL-22) protein of the invention.
XX
SQ   Sequence   179 AA;

  Query Match            100.0%;  Score 903;  DB 23;  Length 179;
  Best Local Similarity  100.0%;  Pred. No. 2.7e-86;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 14
ABB84993
ID   ABB84993 standard; Protein; 179 AA.
XX
AC   ABB84993;
XX
DT   16-MAY-2002  (first entry)
XX
DE   Human PRO10096 protein sequence SEQ ID NO:354.
XX
KW   Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
KW   vulnerary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW   gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW   angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW   age-related macular degeneration; arterial restenosis; angina;
KW   rheumatoid arthritis; myocardial infarction; thrombophlebitis;
```

KW lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW wound healing; chromosome mapping; gene mapping.
XX
OS Homo sapiens.
XX
PN WO200200690-A2.
XX
PD 03-JAN-2002.
XX
PF 20-JUN-2001; 2001WO-US19692.
XX
PR 23-JUN-2000; 2000US-213637P.
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220664P.
PR 28-JUL-2000; 2000WO-US20710.
PR 02-AUG-2000; 2000US-222695P.
PR 17-AUG-2000; 2000US-0643657.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 07-SEP-2000; 2000US-230978P.
PR 18-SEP-2000; 2000US-0664610.
PR 18-SEP-2000; 2000US-0665350.
PR 24-OCT-2000; 2000US-242922P.
PR 08-NOV-2000; 2000US-0709238.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 22-JAN-2001; 2001US-0767609.
PR 28-FEB-2001; 2001US-0796498.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 25-MAY-2001; 2001WO-US17092.
PR 30-MAY-2001; 2001US-0870574.
PR 30-MAY-2001; 2001WO-US17443.
PR 01-JUN-2001; 2001WO-US17800.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-090516/12.
DR N-PSDB; ABL88248.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal -
XX
PS Claim 11; Fig 354; 565pp; English.
XX
CC ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
CC activities, and can be used in gene therapy. The PRO polynucleotides,
CC proteins, agonists and antagonists are useful for treating or diagnosing
CC a cardiovascular, endothelial or angiogenic disorder in a mammal,
CC e.g. cardiac hypertrophy, trauma, cancer, age-related macular
CC degeneration, atherosclerosis, hypertension, arterial restenosis,
CC rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,
CC lymphangitis, tumour angiogenesis (such as breast carcinoma and liver
CC carcinoma) and wound healing. The PRO polynucleotides have applications
CC in molecular biology, including use as hybridisation probes, and in
CC chromosome and gene mapping. ABL88259 to ABL88267 represent primers and
CC probes used in the exemplification of the present invention.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 23; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 15
AAE19237
ID AAE19237 standard; Protein; 179 AA.
XX
AC AAE19237;
XX
DT 21-MAY-2002 (first entry)
XX
DE Human TIF protein.
XX
KW T cell derived inducible factor; TIF; interleukin-21; IL-21; human;
KW STAT transcription factor; acute phase protein; inflammation;
KW Chromosome 12.
XX
OS Homo sapiens.
XX
PN WO200210393-A2.
XX
PD 07-FEB-2002.
XX
PF 27-JUN-2001; 2001WO-US20485.
XX
PR 27-JUL-2000; 2000US-0626617.
XX
PA (LUDW-) LUDWIG INST CANCER RES.
XX
PI Dumoutier L, Renauld J;
XX
DR WPI; 2002-195964/25.
DR N-PSDB; AAD30645.
XX
PT Stimulating expression of STAT transcription factor and inducing
PT production of acute phase protein in a cell, involves contacting a cell
PT capable of expressing STAT with T cell derived inducible factors -
XX
PS Disclosure; Page 64; 64pp; English.
XX
CC The invention relates to nucleic acid molecules encoding T cell
CC derived inducible factors (TIFs) also known as interleukin-21 (IL-21).
CC TIF polynucleotides are upregulated by the cytokine, IL-9. IL-TIF or
CC IL-21 molecules are implicated in activation of STAT transcription
CC factors, acute phase proteins and inflammation. The present sequence
CC is human TIF protein. The TIF gene is located on chromosome 12.
XX
SQ Sequence 179 AA;

Query Match 100.0%; Score 903; DB 23; Length 179;
Best Local Similarity 100.0%; Pred. No. 2.7e-86;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

Search completed: December 5, 2003, 18:16:35
Job time : 61.9323 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: December 5, 2003, 18:16:45 ; Search time 345.883 Seconds
(without alignments)
96.250 Million cell updates/sec

Title: US-10-084-298-2
Perfect score: 903
Sequence: 1 MAALQKSVSSFLMGTLATSC.....EIKAIGELDLLFMSLRNACI 179

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 684280 seqs, 185983659 residues

Total number of hits satisfying chosen parameters: 684280

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
17: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*
18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	903	100.0	179	9	US-09-728-911-15	Sequence 15, Appl
2	903	100.0	179	10	US-09-870-574-2	Sequence 2, Appli
3	903	100.0	179	10	US-09-965-528-18	Sequence 18, Appl
4	903	100.0	179	12	US-10-063-735-154	Sequence 154, App
5	903	100.0	179	12	US-10-216-163-244	Sequence 244, App
6	903	100.0	179	12	US-09-925-055D-8	Sequence 8, Appli
7	903	100.0	179	12	US-10-256-977-2	Sequence 2, Appli
8	903	100.0	179	12	US-09-746-375-2	Sequence 2, Appli
9	903	100.0	179	12	US-10-063-526-154	Sequence 154, App
10	903	100.0	179	12	US-10-066-198-126	Sequence 126, App
11	903	100.0	179	12	US-10-063-586-154	Sequence 154, App
12	903	100.0	179	12	US-10-063-510-154	Sequence 154, App
13	903	100.0	179	12	US-10-063-514-154	Sequence 154, App
14	903	100.0	179	12	US-10-063-516-154	Sequence 154, App
15	903	100.0	179	12	US-10-063-523-154	Sequence 154, App
16	903	100.0	179	12	US-10-063-527-154	Sequence 154, App
17	903	100.0	179	12	US-10-063-528-154	Sequence 154, App
18	903	100.0	179	12	US-10-063-529-154	Sequence 154, App
19	903	100.0	179	12	US-10-063-536-154	Sequence 154, App
20	903	100.0	179	12	US-10-063-540-154	Sequence 154, App
21	903	100.0	179	12	US-10-063-546-154	Sequence 154, App
22	903	100.0	179	12	US-10-063-562-154	Sequence 154, App
23	903	100.0	179	12	US-10-063-564-154	Sequence 154, App
24	903	100.0	179	12	US-10-063-565-154	Sequence 154, App
25	903	100.0	179	12	US-10-063-568-154	Sequence 154, App
26	903	100.0	179	12	US-10-063-570-154	Sequence 154, App
27	903	100.0	179	12	US-10-063-577-154	Sequence 154, App
28	903	100.0	179	12	US-10-063-579-154	Sequence 154, App
29	903	100.0	179	12	US-10-063-581-154	Sequence 154, App
30	903	100.0	179	12	US-10-063-582-154	Sequence 154, App
31	903	100.0	179	12	US-10-063-583-154	Sequence 154, App
32	903	100.0	179	12	US-10-063-584-154	Sequence 154, App
33	903	100.0	179	12	US-10-063-587-154	Sequence 154, App
34	903	100.0	179	12	US-10-063-589-154	Sequence 154, App
35	903	100.0	179	12	US-10-063-591-154	Sequence 154, App
36	903	100.0	179	12	US-10-063-592-154	Sequence 154, App
37	903	100.0	179	12	US-10-063-593-154	Sequence 154, App
38	903	100.0	179	12	US-10-063-596-154	Sequence 154, App
39	903	100.0	179	12	US-10-063-597-154	Sequence 154, App
40	903	100.0	179	12	US-10-063-600-154	Sequence 154, App
41	903	100.0	179	12	US-10-063-602-154	Sequence 154, App
42	903	100.0	179	12	US-10-063-604-154	Sequence 154, App
43	903	100.0	179	12	US-10-063-606-154	Sequence 154, App
44	903	100.0	179	12	US-10-063-607-154	Sequence 154, App
45	903	100.0	179	12	US-10-063-609-154	Sequence 154, App

ALIGNMENTS

```
RESULT 1
US-09-728-911-15
; Sequence 15, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Xu, Wenfeng
;  APPLICANT:  Kindsvogel, Wayne
;  APPLICANT:  Chen, Zhi
;  TITLE OF INVENTION:  Human Cytokine Receptor
;  FILE REFERENCE:  99-93
;  CURRENT APPLICATION NUMBER: US/09/728,911
;  CURRENT FILING DATE:  2000-12-01
;  PRIOR APPLICATION NUMBER:  US 60/169,049
;  PRIOR FILING DATE:  1999-12-03
;  PRIOR APPLICATION NUMBER:  US 60/232,219
;  PRIOR FILING DATE:  2000-09-13
;  PRIOR APPLICATION NUMBER:  US 60/244,610
;  PRIOR FILING DATE:  2000-10-31
;  NUMBER OF SEQ ID NOS:  36
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 15
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-728-911-15

  Query Match             100.0%;  Score 903;  DB 9;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
```

```
Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 2
US-09-870-574-2
; Sequence 2, Application US/09870574
; Patent No. US20020102723A1
; GENERAL INFORMATION:
;  APPLICANT: Gurney,Austin L.
;  APPLICANT:  Aggarwal,Sudeepta
;  APPLICANT:  Xie,Ming-Hong
;  APPLICANT:  Maruoka,Ellen M.
;  APPLICANT:  Foster,Jessica S.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Wood,William I.
;  TITLE OF INVENTION: INTERLEUKIN-22 POLYPEPTIDES, NUCLEIC ACIDS ENCODING
;  TITLE OF INVENTION:  THE SAME AND METHODS FOR THE TREATMENT OF PANCREATIC DISORDERS
;  FILE REFERENCE: P2806-1(US)
;  CURRENT APPLICATION NUMBER: US/09/870,574
;  CURRENT FILING DATE:  2001-05-30
;  PRIOR APPLICATION NUMBER: US 60/169,495
;  PRIOR FILING DATE: 1999-12-07
;  PRIOR APPLICATION NUMBER: PCT/US00/14042
;  PRIOR FILING DATE: 2000-05-22
;  PRIOR APPLICATION NUMBER: PCT/US00/23328
;  PRIOR FILING DATE: 2000-08-24
;  NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 2
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-09-870-574-2

  Query Match             100.0%;  Score 903;  DB 10;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 3
US-09-965-528-18
; Sequence 18, Application US/09965528
; Publication No. US20020187523A1
; GENERAL INFORMATION:
;  APPLICANT: INCYTE GENOMICS, INC.
;  APPLICANT:  TANG, Y. Tom
;  APPLICANT:  YUE, Henry
;  APPLICANT:  LAL, Preeti
;  APPLICANT:  BURFORD, Neil
;  APPLICANT:  BANDMAN, Olga
;  APPLICANT:  BAUGHN, Mariah R.
;  APPLICANT:  AZIMZAI, Yalda
;  APPLICANT:  LU, Dyung Aina M.
;  APPLICANT:  PATTERSON, Chandra
;  TITLE OF INVENTION: EXTRACELLULAR SIGNALING MOLECULES
;  FILE REFERENCE: PF-0701 USA
;  CURRENT APPLICATION NUMBER: US/09/965,528
;  CURRENT FILING DATE:  2001-09-26
;  PRIOR APPLICATION NUMBER: 60/134,949
;  PRIOR FILING DATE: 1999-05-19
;  PRIOR APPLICATION NUMBER: 60/144,270
;  PRIOR FILING DATE: 1999-07-15
;  PRIOR APPLICATION NUMBER: 60/146,700
;  PRIOR FILING DATE: 1999-07-30
;  PRIOR APPLICATION NUMBER: 60/157,508
;  PRIOR FILING DATE: 1999-10-04
;  NUMBER OF SEQ ID NOS: 55
;  SOFTWARE: PERL Program
; SEQ ID NO 18
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Incyte ID No. US20020187523A1 5571181CD1
US-09-965-528-18

  Query Match             100.0%;  Score 903;  DB 10;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 4
US-10-063-735-154
; Sequence 154, Application US/10063735
; Publication No. US20030138882A1
; GENERAL INFORMATION:
;  APPLICANT: Eaton,Dan L.
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Grimaldi,Christopher J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Watanabe,Colin K.
;  APPLICANT:  Wood,William I.
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3230R1C1
;  CURRENT APPLICATION NUMBER: US/10/063,735
;  CURRENT FILING DATE:  2002-05-08
;      Prior Application removed - See Palm or File Wrapper
;  NUMBER OF SEQ ID NOS: 170
; SEQ ID NO 154
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-063-735-154

  Query Match             100.0%;  Score 903;  DB 12;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
```

```
Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 5
US-10-216-163-244
; Sequence 244, Application US/10216163
; Publication No. US20030149239A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C3
; CURRENT APPLICATION NUMBER: US/10/216,163
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 244
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-163-244

Query Match 100.0%; Score 903; DB 12; Length 179;
Best Local Similarity 100.0%; Pred. No. 3.1e-90;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 6

US-09-925-055D-8
; Sequence 8, Application US/09925055D
; Publication No. US20030157096A1
; GENERAL INFORMATION:
; APPLICANT: Kindsvogel, Wayne R.
; APPLICANT: Topouzis, Stavros
; TITLE OF INVENTION: SOLUBLE ZCYTOR11 CYTOKINE RECEPTORS
; FILE REFERENCE: 00-56
; CURRENT APPLICATION NUMBER: US/09/925,055D
; CURRENT FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: US 60/223,827
; PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: US 60/250,876
; PRIOR FILING DATE: 2000-12-01
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 179
; TYPE: PRT
; ORGANISM: homo sapiens
US-09-925-055D-8

Query Match 100.0%; Score 903; DB 12; Length 179;
Best Local Similarity 100.0%; Pred. No. 3.1e-90;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 7
US-10-256-977-2
; Sequence 2, Application US/10256977
; Publication No. US20030157106A1
; GENERAL INFORMATION:
; APPLICANT: Jacobs, Kenneth
; APPLICANT: Pittman, Debra
; APPLICANT: Fouser, Lynette
; APPLICANT: Spaulding, Vikki
; APPLICANT: Xuan, Dejun
; TITLE OF INVENTION: Composition and Method for Treating Inflammatory
; TITLE OF INVENTION: Disorders
; FILE REFERENCE: GI5358 CIP
; CURRENT APPLICATION NUMBER: US/10/256,977
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: US/10/084,298
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: 60/270,823
; PRIOR FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: 60/281,353
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: 60/131,473
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/561,811
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-256-977-2

Query Match 100.0%; Score 903; DB 12; Length 179;

Best Local Similarity 100.0%; Pred. No. 3.1e-90;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 8
US-09-746-375-2
; Sequence 2, Application US/09746375
; Publication No. US20030170823A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Kindsvogel, Wayne
; TITLE OF INVENTION: NOVEL CYTOKINE ZCYTO18
; FILE REFERENCE: 99-106
; CURRENT APPLICATION NUMBER: US/09/746,375
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: US 60/172,105
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: US 60/***,***
; PRIOR FILING DATE: 2000-12-01
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-746-375-2

Query Match 100.0%; Score 903; DB 12; Length 179;
Best Local Similarity 100.0%; Pred. No. 3.1e-90;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 9
US-10-063-526-154
; Sequence 154, Application US/10063526
; Publication No. US20030171550A1
; GENERAL INFORMATION:
; APPLICANT: Eaton,Dan L.
; APPLICANT: Filvaroff,Ellen
; APPLICANT: Gerritsen,Mary E.
; APPLICANT: Goddard,Audrey
; APPLICANT: Godowski,Paul J.
; APPLICANT: Grimaldi,Christopher J.
; APPLICANT: Gurney,Austin L.
; APPLICANT: Watanabe,Colin K.
; APPLICANT: Wood,William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3230R1C1
; CURRENT APPLICATION NUMBER: US/10/063,526
; CURRENT FILING DATE: 2002-05-02
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 170
; SEQ ID NO 154
; LENGTH: 179
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-063-526-154

Query Match 100.0%; Score 903; DB 12; Length 179;
Best Local Similarity 100.0%; Pred. No. 3.1e-90;
Matches 179; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
```

RESULT 10
US-10-066-198-126
; Sequence 126, Application US/10066198
; Publication No. US20030170721A1
; GENERAL INFORMATION:
; APPLICANT: Avi J. Ashkenazi
; APPLICANT: Kevin P. Baker
; APPLICANT: David A. Botstein
; APPLICANT: Luc Desnoyers
; APPLICANT: Dan L. Eaton
; APPLICANT: Napoleone Ferrara
; APPLICANT: Sherman Fong
; APPLICANT: Wei-Qiang Gao
; APPLICANT: Hanspeter Gerber
; APPLICANT: Mary B. Gerritsen
; APPLICANT: Audrey Goddard
; APPLICANT: Paul J. Godowski
; APPLICANT: Austin L. Gurney
; APPLICANT: Ivar J. Kljavin
; APPLICANT: Jennie P. Mather
; APPLICANT: Mary A. Napier
; APPLICANT: James Pan
; APPLICANT: Nicholas F. Paoni
; APPLICANT: Margaret Ann Roy
; APPLICANT: Timothy A. Stewart
; APPLICANT: Daniel Tumas
; APPLICANT: Colin K. Watanabe
; APPLICANT: P.Mickey Williams
; APPLICANT: William I. Wood
; APPLICANT: Zemin Zang
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3130R1C6
; CURRENT APPLICATION NUMBER: US/10/066,198
; CURRENT FILING DATE: 2002-02-01
; PRIOR APPLICATION NUMBER: 10/002,796
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062285

; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066840
; PRIOR FILING DATE: 1997-11-25
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/081049
; PRIOR FILING DATE: 1998-04-08
; PRIOR APPLICATION NUMBER: 60/095998
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/097000
; PRIOR FILING DATE: 1998-08-18
; PRIOR APPLICATION NUMBER: 60/099601
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100858
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106032
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/109304
; PRIOR FILING DATE: 1998-11-20
; PRIOR APPLICATION NUMBER: 60/125778
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/139695
; PRIOR FILING DATE: 1999-06-15
; PRIOR APPLICATION NUMBER: 60/145070
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/149396
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 08/918874
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 08/933821
; PRIOR FILING DATE: 1997 -09-19
; PRIOR APPLICATION NUMBER: 08/960507
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 09/114844
; PRIOR FILING DATE: 1998-07-14
; PRIOR APPLICATION NUMBER: 09/136801
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: 09/136804
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: 09/136828
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: 09/158342
; PRIOR FILING DATE: 1998-09-21
; PRIOR APPLICATION NUMBER: 09/180997
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 09/202088
; PRIOR FILING DATE: 1998-12-08
; PRIOR APPLICATION NUMBER: 09/254311
; PRIOR FILING DATE: 1999-03-03
; PRIOR APPLICATION NUMBER: 09/254460
; PRIOR FILING DATE: 1999-03-09
; PRIOR APPLICATION NUMBER: 09/254465
; PRIOR FILING DATE: 1999-03-05
; PRIOR APPLICATION NUMBER: 09/284663
; PRIOR FILING DATE: 1999-04-15
; PRIOR APPLICATION NUMBER: 09/332928
; PRIOR FILING DATE: 1999-06-14
; PRIOR APPLICATION NUMBER: 09/332929
; PRIOR FILING DATE: 1999-06-14
; PRIOR APPLICATION NUMBER: 09/333075
; PRIOR FILING DATE: 1999-06-14
; PRIOR APPLICATION NUMBER: 09/333077
; PRIOR FILING DATE: 1999-06-14
; PRIOR APPLICATION NUMBER: 09/380137
; PRIOR FILING DATE: 1999-08-25
; PRIOR APPLICATION NUMBER: 09/380138
; PRIOR FILING DATE: 1999-08-25
; PRIOR APPLICATION NUMBER: 09/380139
; PRIOR FILING DATE: 1999-08-25
; PRIOR APPLICATION NUMBER: 09/403296
; PRIOR FILING DATE: 1999-10-18
; PRIOR APPLICATION NUMBER: 09/403297
; PRIOR FILING DATE: 1999-10-18
; PRIOR APPLICATION NUMBER: 09/423741
; PRIOR FILING DATE: 1999-11-10
; PRIOR APPLICATION NUMBER: 09/423844
; PRIOR FILING DATE: 1999-11-12
; PRIOR APPLICATION NUMBER: 09/522342
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: 09/548815
; PRIOR FILING DATE: 2000-04-13
; PRIOR APPLICATION NUMBER: 09/664610
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: 09/665350
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: 09/709238
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 09/767609
; PRIOR FILING DATE: 2001-01-22
; PRIOR APPLICATION NUMBER: 09/802706
; PRIOR FILING DATE: 2001-03-09
; PRIOR APPLICATION NUMBER: 09/808689
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: 09/866028
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 09/870574
; PRIOR FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: 09/872035
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: 09/886342
; PRIOR FILING DATE: 2001-06-19
; PRIOR APPLICATION NUMBER: PCT/US98/14552
; PRIOR FILING DATE: 1998-07-14
; PRIOR APPLICATION NUMBER: PCT/US98/18824
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: PCT/US98/19093
; PRIOR FILING DATE: 1998-09-14
; PRIOR APPLICATION NUMBER: PCT/US98/19330
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: PCT/US98/19437
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: PCT/US98/24855
; PRIOR FILING DATE: 1998-11-20
; PRIOR APPLICATION NUMBER: PCT/US98/25108
; PRIOR FILING DATE: 1998-12-01
; PRIOR APPLICATION NUMBER: PCT/US98/25190
; PRIOR FILING DATE: 1998-11-25
; PRIOR APPLICATION NUMBER: PCT/US99/05028

```
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: PCT/US99/12252
;  PRIOR FILING DATE: 1999-06-02
;  PRIOR APPLICATION NUMBER: PCT/US99/20111
;  PRIOR FILING DATE: 1999-09-01
;  PRIOR APPLICATION NUMBER: PCT/US99/20594
;  PRIOR FILING DATE: 1999-09-08
;  PRIOR APPLICATION NUMBER: PCT/US99/21090
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: PCT/US99/21547

  Query Match             100.0%;  Score 903;  DB 12;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 11
US-10-063-586-154
; Sequence 154, Application US/10063586
; Publication No. US20030176684A1
; GENERAL INFORMATION:
;  APPLICANT: Eaton,Dan L.
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Grimaldi,Christopher J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Watanabe,Colin K.
;  APPLICANT:  Wood,William I.
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3230R1C1
;  CURRENT APPLICATION NUMBER: US/10/063,586
;  CURRENT FILING DATE:  2002-05-03
;     Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 170
; SEQ ID NO 154
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-063-586-154

  Query Match             100.0%;  Score 903;  DB 12;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 12
US-10-063-510-154
; Sequence 154, Application US/10063510
; Publication No. US20030180837A1
; GENERAL INFORMATION:
;  APPLICANT: Eaton,Dan L.
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Grimaldi,Christopher J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Watanabe,Colin K.
;  APPLICANT:  Wood,William I.
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3230R1C1
;  CURRENT APPLICATION NUMBER: US/10/063,510
;  CURRENT FILING DATE:  2002-05-01
;  Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 170
; SEQ ID NO 154
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-063-510-154

  Query Match             100.0%;  Score 903;  DB 12;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 13
US-10-063-514-154
; Sequence 154, Application US/10063514
; Publication No. US20030181707A1
; GENERAL INFORMATION:
;  APPLICANT: Eaton,Dan L.
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Grimaldi,Christopher J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Watanabe,Colin K.
;  APPLICANT:  Wood,William I.
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3230R1C1
;  CURRENT APPLICATION NUMBER: US/10/063,514
;  CURRENT FILING DATE:  2002-05-01
;  Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 170
; SEQ ID NO 154
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-063-514-154

  Query Match             100.0%;  Score 903;  DB 12;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 14
US-10-063-516-154
; Sequence 154, Application US/10063516
; Publication No. US20030181708A1
; GENERAL INFORMATION:
;  APPLICANT: Eaton,Dan L.
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Grimaldi,Christopher J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Watanabe,Colin K.
;  APPLICANT:  Wood,William I.
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3230R1C1
;  CURRENT APPLICATION NUMBER: US/10/063,516
;  CURRENT FILING DATE:  2002-05-01
;  Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 170
; SEQ ID NO 154
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-063-516-154

  Query Match             100.0%;  Score 903;  DB 12;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


RESULT 15
US-10-063-523-154
; Sequence 154, Application US/10063523
; Publication No. US20030181636A1
; GENERAL INFORMATION:
;  APPLICANT: Eaton,Dan L.
;  APPLICANT:  Filvaroff,Ellen
;  APPLICANT:  Gerritsen,Mary E.
;  APPLICANT:  Goddard,Audrey
;  APPLICANT:  Godowski,Paul J.
;  APPLICANT:  Grimaldi,Christopher J.
;  APPLICANT:  Gurney,Austin L.
;  APPLICANT:  Watanabe,Colin K.
;  APPLICANT:  Wood,William I.
;  TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;  TITLE OF INVENTION:  ACIDS ENCODING THE SAME
;  FILE REFERENCE: P3230R1C1
;  CURRENT APPLICATION NUMBER: US/10/063,523
;  CURRENT FILING DATE:  2002-05-02
;  Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 170
; SEQ ID NO 154
;   LENGTH: 179
;   TYPE: PRT
;   ORGANISM: Homo Sapien
US-10-063-523-154

  Query Match             100.0%;  Score 903;  DB 12;  Length 179;
  Best Local Similarity   100.0%;  Pred. No. 3.1e-90;
  Matches  179;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAALQKSVSSFLMGTLATSCLLLLALLVQGGAAAPISSHCRLDKSNFQQPYITNRTFMLA 60

Qy         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KEASLADNNTDVRLIGEKLFHGVSMSERCYLMKQVLNFTLEEVLFPQSDRFQPYMQEVVP 120

Qy        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 FLARLSNRLSTCHIEGDDLHIQRNVQKLKDTVKKLGESGEIKAIGELDLLFMSLRNACI 179


Search completed: December  5, 2003, 18:32:11
Job time : 346.883 secs
```